Association of Factor V Leiden with Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data
Bakhtawar K. Mahmoodi,Vinicius Tragante,Marcus E. Kleber,Michael V. Holmes,Michael V. Holmes,Amand F. Schmidt,Amand F. Schmidt,Raymond O McCubrey,Laurence J. Howe,Kenan Direk,Hooman Allayee,Ekaterina V Baranova,Peter S. Braund,Peter S. Braund,Graciela E. Delgado,Niclas Eriksson,Crystel M. Gijsberts,Yan Gong,Jaana Hartiala,Mahyar Heydarpour,Mahyar Heydarpour,Gerard Pasterkamp,Salma Kotti,Pekka Kuukasjärvi,Petra A. Lenzini,Daniel Levin,Leo-Pekka Lyytikäinen,Jochen D. Muehlschlegel,Jochen D. Muehlschlegel,Christopher P. Nelson,Christopher P. Nelson,Kjell Nikus,Anna P. Pilbrow,W.H. Wilson Tang,W.H. Wilson Tang,Sander W. van der Laan,Jessica van Setten,Ragnar O. Vilmundarson,John E. Deanfield,Panos Deloukas,Frank Dudbridge,Stefan James,Ify R. Mordi,Andrej Teren,Thomas O. Bergmeijer,Simon C. Body,Michiel L. Bots,Michiel L. Bots,Ralph Burkhardt,Rhonda M. Cooper-DeHoff,Sharon Cresci,Nicolas Danchin,Robert N. Doughty,Diederick E. Grobbee,Emil Hagström,Stanley L. Hazen,Stanley L. Hazen,Claes Held,Imo E. Hoefer,G. Kees Hovingh,Julie A. Johnson,Marcin P. Kaczor,Mika Kähönen,Olaf H. Klungel,Jari Laurikka,Terho Lehtimäki,Anke H. Maitland-van der Zee,Anke H. Maitland-van der Zee,Ruth McPherson,Colin N. A. Palmer,Adriaan O. Kraaijeveld,Carl J. Pepine,Marek Sanak,Naveed Sattar,Markus Scholz,Tabassome Simon,Tabassome Simon,John A. Spertus,Alexandre F.R. Stewart,Wojciech Szczeklik,Joachim Thiery,Frank L.J. Visseren,Johannes Waltenberger,A. Mark Richards,A. Mark Richards,Chim C. Lang,Vicky A. Cameron,Axel Åkerblom,Guillaume Paré,Guillaume Paré,Winfried März,Winfried März,Winfried März,Nilesh J. Samani,Nilesh J. Samani,Aroon D. Hingorani,Jurriën M. ten Berg,Lars Wallentin,Folkert W. Asselbergs,Folkert W. Asselbergs,Riyaz S. Patel,Riyaz S. Patel +101 more
Reads0
Chats0
TLDR
Factor V Leiden was not associated with increased risk of subsequent atherothrombotic events and mortality in high-risk participants with established and treated CHD, and risk estimates for the secondary outcomes including stroke, coronary revascularization, cardiovascular mortality, and all-cause mortality were close to identity.Abstract:
Background: Studies examining the role of factor V Leiden among patients at higher risk of atherothrombotic events, such as those with established coronary heart disease (CHD), are lacking. Given t...read more
Citations
More filters
Journal ArticleDOI
Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study.
Michael G. Levin,Michael G. Levin,Derek Klarin,Derek Klarin,Themistocles L. Assimes,Themistocles L. Assimes,Matthew S. Freiberg,Matthew S. Freiberg,Erik Ingelsson,Julie Lynch,Pradeep Natarajan,Christopher J. O'Donnell,Daniel J. Rader,Philip S. Tsao,Kyong-Mi Chang,Kyong-Mi Chang,Benjamin F. Voight,Scott M. Damrauer,Scott M. Damrauer,VA Million Veteran Program +19 more
TL;DR: In this article, the association between genetic liability to smoking and risk of coronary artery disease, peripheral artery disease (PAD), and large-artery stroke was found to be strong risk factor for CAD, PAD, and stroke.
Posted ContentDOI
Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study
Michael G. Levin,Michael G. Levin,Derek Klarin,Derek Klarin,Themistocles L. Assimes,Themistocles L. Assimes,Matthew S. Freiberg,Matthew S. Freiberg,Erik Ingelsson,Erik Ingelsson,Julie Lynch,Pradeep Natarajan,Christopher J. O'Donnell,Daniel J. Rader,Philip S. Tsao,Kyong-Mi Chang,Kyong-Mi Chang,Benjamin F. Voight,Scott M. Damrauer,Scott M. Damrauer +19 more
TL;DR: Genetic liability to smoking is a strong, causal risk factor for CAD, PAD, and stroke, although the effect of smoking is strongest for PAD.
Journal ArticleDOI
Risk Prediction of Cardiovascular Events by Exploration of Molecular Data with Explainable Artificial Intelligence.
TL;DR: In this paper, the authors review the most recent advances in risk prediction of recurrent cardiovascular events, and discuss the value of molecular data and biomarkers for understanding patient risk in a systems biology context.
Journal ArticleDOI
Traditional risk factors and combined genetic markers of recurrent ischemic stroke in adults
Lamia Mbarek,Salma Sakka,Fatma Megdiche,Nouha Farhat,Khadija Maalla,Dhaker Turki,S. Feki,Ahmed Rebai,Mariem Dammak,Choumous Kallel,Chokri Mhiri +10 more
TL;DR: In this article, the authors investigate the combined effect of traditional risk factors and combined genetic markers of recurrent arterial ischemic stroke (AIS) on the occurrence of a second CSA.
Journal ArticleDOI
Association of factor V Leiden R506Q, FXIIIVal34Leu, and MTHFR C677T polymorphisms with acute myocardial infarction
Amin Golestani,Atefeh Rahimi,N. Moridi,Gholamreza Anani-Sarab,Fatemeh Salmani,Kazem Dastjerdi,Nahid Azdaki,Seyed Mehdi Sajjadi +7 more
TL;DR: In this paper , the authors investigated the association of three thrombophilic polymorphisms including factor V Leiden (FVL), MTHFRC677T (methylenetetrahydrofolate reductase), and Coagulation factor XIIIVal34Leu with AMI in East of Iran.
References
More filters
Journal ArticleDOI
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin,Richard C. Becker,Andrzej Budaj,Christopher P. Cannon,Håkan Emanuelsson,Claes Held,Jay Horrow,Steen Husted,Stefan James,Hugo A. Katus,Kenneth W. Mahaffey,Benjamin M. Scirica,Allan M. Skene,Philippe Gabriel Steg,Robert F. Storey,Robert A. Harrington +15 more
TL;DR: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
Journal ArticleDOI
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Zeneng Wang,Elizabeth Klipfell,Brian J. Bennett,Robert A. Koeth,Bruce S. Levison,Brandon DuGar,Ariel E. Feldstein,Earl B. Britt,Xiaoming Fu,Yoon-Mi Chung,Yuping Wu,Phil Schauer,Jonathan D. Smith,Hooman Allayee,W.H. Wilson Tang,Joseph A. DiDonato,Aldons J. Lusis,Stanley L. Hazen +17 more
TL;DR: Discovery of a relationship between gut-flora-dependent metabolism of dietary phosphatidylcholine and CVD pathogenesis provides opportunities for the development of new diagnostic tests and therapeutic approaches for atherosclerotic heart disease.
Journal ArticleDOI
Mutation in blood coagulation factor V associated with resistance to activated protein C
Rogier M. Bertina,Bobby P. C. Koeleman,Ted Koster,Frits R. Rosendaal,Richard J. Dirven,Hans De Ronde,Pieter A. van der Velden,Pieter H. Reitsma +7 more
TL;DR: It is demonstrated that the phenotype of APC resistance is associated with hetero-zygosity or homozygosity for a single point mutation in the factor V gene which predicts the synthesis of a factor V molecule that is not properly inactivated by APC.
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
C. Michael Gibson,Roxana Mehran,Christoph Bode,Jonathan L. Halperin,Freek W Verheugt,Peter Wildgoose,Mary Birmingham,Juliana Ianus,Paul W. Burton,Martin van Eickels,Serge Korjian,Yazan Daaboul,Gregory Y.H. Lip,Marc Cohen,Steen Elkjær Husted,Eric D. Peterson,Keith A.A. Fox +16 more
TL;DR: In participants with atrial fibrillation undergoing PCI with placement of stents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose thrombolysis in Myocardial Infarction plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding.
Related Papers (5)
Association of Chromosome 9p21 with Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data
Riyaz S. Patel,Amand F. Schmidt,Vinicius Tragante,Raymond O McCubrey,Michael V. Holmes,Michael V. Holmes,Michael V. Holmes,Laurence J. Howe,Kenan Direk,Axel Åkerblom,Karin Leander,Salim S. Virani,Karol Kamiński,Jochen D. Muehlschlegel,Marie-Pierre Dubé,Hooman Allayee,Peter Almgren,Maris Alver,Ekaterina V Baranova,Hassan Behlouli,Bram Boeckx,Peter S. Braund,Peter S. Braund,Lutz P. Breitling,Graciela E. Delgado,Nubia E. Duarte,Line Dufresne,Niclas Eriksson,Luisa Foco,Crystel M. Gijsberts,Yan Gong,Jaana Hartiala,Mahyar Heydarpour,Mahyar Heydarpour,Jaroslav A. Hubacek,Marcus E. Kleber,Daniel Kofink,Pekka Kuukasjärvi,Vei-Vei Lee,Andreas Leiherer,Petra A. Lenzini,Daniel Levin,Leo-Pekka Lyytikäinen,Nicola Martinelli,Ute Mons,Christopher P. Nelson,Christopher P. Nelson,Kjell Nikus,Anna P. Pilbrow,Rafał Płoski,Yan V. Sun,Michael W.T. Tanck,W.H. Wilson Tang,Stella Trompet,Sander W. van der Laan,Jessica van Setten,Ragnar O. Vilmundarson,Chiara Viviani Anselmi,Efthymia Vlachopoulou,Eric Boerwinkle,Carlo Briguori,John F. Carlquist,Kathryn F. Carruthers,Gavino Casu,John E. Deanfield,Panos Deloukas,Frank Dudbridge,Natalie K Fitzpatrick,Bruna Gigante,Stefan James,Marja-Liisa Lokki,Paulo A. Lotufo,Nicola Marziliano,Ify Mordi,Joseph B. Muhlestein,Chris Newton Cheh,Jan Pitha,Christoph H. Saely,Ayman Samman-Tahhan,Pratik B. Sandesara,Andrej Teren,Adam Timmis,Adam Timmis,Frans Van de Werf,Els Wauters,Arthur A.M. Wilde,Ian Ford,David J. Stott,Ale Algra,Maria G. Andreassi,Diego Ardissino,Benoit J. Arsenault,Christie M. Ballantyne,Thomas O. Bergmeijer,Connie R. Bezzina,Simon C. Body,Simon C. Body,Peter Bogaty,Gert J. de Borst,Hermann Brenner,Ralph Burkhardt,Clara Carpeggiani,Gianluigi Condorelli,Rhonda M. Cooper-DeHoff,Sharon Cresci,Ulf de Faire,Robert N. Doughty,Heinz Drexel,James C. Engert,Keith A.A. Fox,Domenico Girelli,Emil Hagström,Stanley L. Hazen,Stanley L. Hazen,Claes Held,Harry Hemingway,Imo E. Hoefer,G. Kees Hovingh,Julie A. Johnson,Pim A. de Jong,J. Wouter Jukema,J. Wouter Jukema,Marcin P. Kaczor,Mika Kähönen,Jiri Kettner,Marek Kiliszek,Olaf H. Klungel,Bo Lagerqvist,Diether Lambrechts,Jari Laurikka,Terho Lehtimäki,Dan Lindholm,Bakhtawar K. Mahmoodi,Anke H. Maitland-van der Zee,Anke H. Maitland-van der Zee,Ruth McPherson,Olle Melander,Andres Metspalu,Witold Pepinski,Oliviero Olivieri,Grzegorz Opolski,Colin N. A. Palmer,Gerard Pasterkamp,Carl J. Pepine,Alexandre C. Pereira,Louise Pilote,Arshed A. Quyyumi,A. Mark Richards,A. Mark Richards,Marek Sanak,Markus Scholz,Agneta Siegbahn,Juha Sinisalo,J. Gustav Smith,John A. Spertus,Alexandre F.R. Stewart,Wojciech Szczeklik,Anna Szpakowicz,Jurriën M. ten Berg,George Thanassoulis,George Thanassoulis,Joachim Thiery,Yolanda van der Graaf,Frank L.J. Visseren,Johannes Waltenberger,Pim van der Harst,Jean-Claude Tardif,Naveed Sattar,Chim C. Lang,Guillaume Paré,Guillaume Paré,James M. Brophy,Jeffrey L. Anderson,Winfried März,Winfried März,Winfried März,Lars Wallentin,Vicky A. Cameron,Benjamin D. Horne,Nilesh J. Samani,Aroon D. Hingorani,Folkert W. Asselbergs +181 more